- €496.49m
- €491.69m
- €115.50m
- 100
- 15
- 69
- 68
Annual balance sheet for Pharmanutra SpA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 20.8 | 33.9 | 26.9 | 25.1 | 29.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 16.7 | 17.8 | 23.8 | 22.7 | 24.3 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 40.4 | 55.5 | 58.7 | 58.7 | 65 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.8 | 8.37 | 17.1 | 26.4 | 25.7 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 51.7 | 71.4 | 100 | 112 | 117 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.1 | 16.7 | 25.8 | 27.6 | 27.3 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 14 | 26.3 | 49.2 | 58 | 55.3 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 37.7 | 45.1 | 50.9 | 54.4 | 62.2 |
| Total Liabilities & Shareholders' Equity | 51.7 | 71.4 | 100 | 112 | 117 |
| Total Common Shares Outstanding |